Project Grant SB1AI191871
Award Date 9/24/25
Completion Date 8/31/28
Dollars Obligated $993K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92121, USA
Similar Awards
- Federal Project Grant Award Summary Inhalon Biopharma, Inc. received a $1,013,468 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on September 1, 2025, with completion scheduled for July 31, 2028. The company is developing IN-003PI, a passive immunization therapeutic comprised of two neutralizing monoclonal antibodies (mAbs) targeting human metapneumovirus (hMPV) fusion...
- Mapp Biopharmaceutical, Inc. received a $294,583 Project Grant awarded June 9, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) administered by the National Institute of Allergy and Infectious Diseases to develop a novel cost-effective multispecific therapeutic for dengue virus infection. The deliverable is a tri-specific antibody fragment molecule designed to enhance therapeutic efficacy against dengue by targeting two distinct epitopes of the envelope protein,...
- Federal Project Grant Award Summary Protabit LLC received a $304,602 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on August 7, 2025, with completion targeted for July 31, 2026. The award funds development of a novel protein engineering platform for high-throughput engineering of bispecific antibodies—specifically, co-evolved bispecific antibodies (CEBAbs) that comprise two...
- Federal Grant Award Summary Zabbio, Inc. received a $248,531 Project Grant award from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 8, 2025, with a completion date of July 31, 2026. The award supports the development of a monoclonal antibody (MAB) therapeutic for neonatal herpes simplex virus (HSV) infections, specifically focusing on HSV8, a broadly neutralizing antibody with demonstrated efficacy...
- Federal Project Grant Award Summary L2 Diagnostics LLC received a $299,954 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 15, 2025, with completion targeted for August 31, 2027. The award funds a Phase I feasibility Small Business Technology Transfer (STTR) project to develop PFAG, a multivalent peptide vaccine against malaria. The vaccine comprises synthetic peptides...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts General Hospital $364,484 through the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 25, 2025, to support research on soluble guanylate cyclase (SGC) pathway activation as a novel bronchodilation strategy for respiratory syncytial virus (RSV) bronchiolitis in pediatric populations. The research project, with an ultimate completion date of June 30, 2027,...
- Federal Project Grant Award Summary Microbiotix, Inc. received a $299,946 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 22, 2025, with completion targeted for August 31, 2027. The award supports the development of novel benzyl-piperidine (BP) antifungal agents to treat intractable mucormycosis infections caused by the Mucorales fungal order, a World Health...
- Federal Project Grant Award Summary Seattle Children's Research Institute received a $862,347 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 20, 2026, through January 31, 2031. The grant funds research investigating the impact of respiratory syncytial virus (RSV) vaccination and preterm delivery on maternal RSV-specific peripheral and mucosal immunity. The primary...
- Federal Grant Award Summary Boston University Medical Campus received a $189,276 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025, through July 31, 2030. The award supports the development of an agent-based modeling framework to characterize Respiratory Syncytial Virus (RSV) burden and evaluate prevention strategies across multiple at-risk populations in the...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Johns Hopkins University a $775,187 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) beginning August 1, 2025, through July 31, 2030. This research initiative will systematically investigate antibody responses to novel respiratory syncytial virus (RSV) vaccines in immunosuppressed persons (ISPs), a high-risk population with a 40% hospitalization risk...